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Introduction 
Infantile hepatic hemangioma (IHH) is the most common benign tumor of the liver in the first 
year of age. Treatment for IHH is historically medical therapy including corticosteroids, 
interferon α, vincristine and cyclophosphamide (1). Nevertheless, significant morbidity and 
mortality have been reported (2). Since 2010 few experiences of patients with IHH successfully 
treated with oral propranolol as second- or first line therapy are reported (3). Herein, we describe 
a particular case of life-threatening IHH successfully treated with oral propranolol as first line 
approach. 
Case Description 
A 4-month-old female was referred because of abdominal distension. Prenatal sonograms were 
normal. Abdominal examination was remarkable for hepatomegaly and prominent venous 
pattern.  Skin examination was negative for hemangiomas. Abnormal laboratory findings were: 
hemoglobin 7.4 g/dL, total proteins 5.8 g/dL (n.v.6.8-8.7), AST 94 IU/mL (n.v.16-65), γGT 104 
UI/L (n.v.0-34), LDH 838 U/L (n.v.120-300). Abdominal ultrasound revealed marked 
hepatomegaly with multiple hypoechoic lesions. An abdomen dynamic contrast-enhanced 
magnetic resonance imaging (MRI) showed massive hepatomegaly with innumerable masses 
hypointense in T1 and hyperintense in T2 replacing most of the normal hepatic parenchyma 
(fig.1). Thyroid function tests revealed: TSH 69.96 µIU/mL, (n.v.0.55-6.70), FT3 1.6 pg/mL 
(n.v.1.50-6.40), FT4 1.62 ng/dL (n.v.0.80-1.80). Echocardiogram showed no signs of volume 
overload. A diagnosis of IHH diffuse pattern with consumptive hypothyroidism was made. The 
patient suddenly developed severe respiratory distress due to the rapidly increasing abdominal 
distension and she was transferred to Intensive Care Unit. Propranolol at 2 mg/kg per day and 
prednisone at 2 mg/kg per day through nasogastric tube were started. Thyroxine replacement 
10.1 increased up to 12.8 µg/kg per day was also delivered. Her clinical conditions improved and 
she was weaned from O2 therapy. After 6 weeks a MRI evaluation demonstrated a mild 
reduction of the lesions, therefore prednisone was decreased to 1 mg/kg per day for 2 weeks and to 
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0.5 mg/kg per day for 2 more weeks while propranolol was continued. After 12 months a MRI 
showed an impressive involution of the liver lesions (Fig. 2), therefore thyroxine administration 
was slowly decreased. A complete regression of the lesions was documented after 24 months and 
propranolol was discontinued. No adverse effects of propranolol were observed. At present, the 
girl is three years old with normal neurological and auxologic development, under follow-up. 
Discussion 
The diffuse form of IHH has an extensive hepatic involvement with a near total replacement of 
the liver parenchyma by innumerable lesions. Massive hepatomegaly causes compression of the 
inferior vena cava and thoracic cavity, resulting in respiratory distress, abdominal compartment 
syndrome and multi-organ failure (2). Consumptive hypothyroidism is a rare complication of 
IHH (4). The mainstay of treatment for symptomatic IHH has traditionally included primarily 
corticosteroids, followed by interferon α, vincristine and cyclophosphamide for resistant lesions 
(2). The use of these agents, however, may be associated with well-known side effects. Surgical 
approach including embolization, hepatic artery ligation, hepatic resection and liver 
transplantation has been reported for more severely ill children but it may be associated with a 
high rate of complications such as bleeding and liver necrosis (1). In 2008 propranolol was 
serendipitously discovered to promote regression of IH; its use in cutaneous hemangioma is now 
considered as standard-of-care first-line systemic therapy (5). Propranolol was initially employed 
in IHH treatment as second-line therapy in patients resistant to conventional medical therapy. 
Since 2010, sixteen patients successfully treated with propranolol as first-line approach have 
been published (3). All these patients presented cutaneous hemangiomas which were 
interestingly absent in our case. Furthermore, in our case propranolol was started in Intensive 
Care Unit through nasogastric tube. 
In conclusion, we underline the impressive efficacy of propranolol in a life threatening situation 
and the safety of prolonged administration. 
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